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tion at 9p, which includes CDKN1A/CDKN1B (Moore et al., 2012; Kuo
et al., 2010). VHL mutation is common in RCCA (57%), whereas PIK3CA
mutation is common inOCCA (33%) (Gnarra et al., 1994; Kuo et al., 2009).
We present a case of a young woman with a congenital genital
anomaly diagnosed with PVCCA. She was treated with concurrent che-
moradiotherapy (CCRT) and remains recurrence free to date.We exam-
ined the tumor for chromosomal copy number alterations (CNA) and
genetic mutations and compared the alterations with those commonly
reported for RCCA and OCCA.Introduction
Vaginal cancer accounts for only 1–2% of female genitalmalignancies
(Creasman et al., 1998). Primary vaginal clear cell adenocarcinoma
(PVCCA) is particularly uncommon, as 80–90% of vaginal cancers
are squamous cell carcinoma (Creasman et al., 1998). PVCCA generally
occurs in young women with genital tract anomalies and intrauterine
diethylstilbestrol (DES) exposure and is very rare in women with no
history of DES exposure (Hanselaar et al., 1997). Neither the optimal
therapeutic strategy nor the molecular characteristics of this disease
have been elucidated. Four reported cases of non-DES-exposed PVCCA
were associated with congenital genital tract anomalies (Uehara et al.,
2010; Tanaka et al., 1994), suggesting that congenital genital anomalies
are common to bothDES-exposed PVCCAand non-DES-exposed PVCCA.
Despite the apparent familial nature of this disease, the genetic charac-
teristics of PVCCA are still unknown. Clear cell adenocarcinoma (CCA) is
a common histologic type of renal and ovarian carcinoma. Renal CCA
(RCCA) frequently exhibits chromosomal loss at 3p (92.2%), which
includes VHL, and gain at 5q (60.2%), whereas ovarian CCA (OCCA)tsutoshi-tky@umin.ac.jp
a-tky@umin.ac.jp (K. Kawana),
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A 25-year-old woman was referred to our hospital with abnormal
vaginal bleeding. Hermedical history included a right ectopic ureteral or-
iﬁce repaired by surgery during childhood, and she was also diagnosed
with a septate uterus. She had no history of prenatal DES exposure or sex-
ual intercourse. Colposcopy showed an entirely circumferential vaginal
tumor, primarily at the distal side (Fig. 1A-1) and not affecting the uterine
cervix. Vaginal biopsy showed large cells with clear cytoplasm, enlarged
nucleoli, and tubular structures lined by hobnail cells (Fig. 1A-2).
Magnetic resonance imaging (MRI) revealed a tumor, N6 cm in size,
expanded inside the vagina without parametrial invasion (Fig. 1A-3).
Computed tomography (CT) also showed the presence of the tumor as
well as right renal atrophy and compensatory hypertrophy of the
left kidney, but no metastasis was detected by positron emission
tomography–CT. The cancer was diagnosed as stage Ι PVCCA (Interna-
tional Federation of Gynecology and Obstetrics). Considering the com-
plexity of surgery and the limited therapeutic effects of radiotherapy
alone, CCRT was selected as the treatment strategy after obtaining
informed consent from the patient. Weekly cisplatin (40 mg/m2,
6 cycles) and a combination of external radiotherapy (1.8 Gy, 28 times)
and high-dose-rate intracavitary brachytherapy (6 Gy, 6 times) were
administered. After 1.5 months, colposcopy, vaginal biopsy, and MRI
(Fig. 1B-1, B-2, B-3) showed a drastic decrease in tumor volume. The
following month, vaginal biopsy conﬁrmed a pathological complete re-
sponse. The patient has been recurrence free for 5 years following CCRT.
Clear cell adenocarcinoma (CCA) is a common histologic type of
renal cell and ovarian carcinomas. Therefore, we hypothesized that
PVCCA may share common genetic characteristics with CCA arising inrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Colposcopic, microscopic, andmagnetic resonance imaging ﬁndings. (A) Before treatment. (B) 1.5 months after concurrent chemoradiotherapy. (A-1) Colposcopy shows a vaginal
tumor, with extension beyond the lower third of the vagina. (A-2) Histologically (high power), cancer cells had clear cytoplasm, enlarged nucleoli, and tubular structures lined by hobnail
cells. (A-3) The axial T2-weighted image shows a N6-cm vaginal tumor. (B-1) Colposcopy showed tumor disappearance on the right side of the vagina. (B-2) Vaginal biopsy (low power)
showed a signiﬁcant reduction in viable cells. (B-3) The axial T2-weighted image showed a tiny residual tumor (low intensity) with ﬂuid collection (high intensity) inside the vagina.
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obtaining informed consent and approval by the appropriate institu-
tional ethics committee. Samples were embedded in optimal cutting
temperature compound and were cut into 4-μm sections. Genomic
DNAwas isolated from the tumor and control samples (lymphocyte pel-
let from the patient's blood) using the QIAamp DNA Easy Kit (Qiagen,
Valencia, CA). RNAwas also extracted from the tumor using the RNeasy
Mini Kit (Qiagen, Valencia, CA). We then performed single nucleotide
polymorphism (SNP) typing array to evaluate chromosomal CNA
using the Human Mapping 250K NSP Array (Affymetrix, Santa Clara,
CA). The SNP array revealed several CNA, including 5 loci with copy
number neutral loss of heterozygosity (gain of one allele and loss
of the other allele) at chromosomes 1q, 9p, 12p, 16q, and 20q (Fig. 2A
and Table 1). Among the CNA, chromosomal gain was noted at
20q13.13–20q13.33, and loss of heterozygosity, at 9p22.1–9p21.3,
which include the cancer-related genes, ZNF217 and CDKN2A/2B,
respectively (Table 1).
Next, we analyzed mutations in PIK3CA (common in OCCA) and
VHL (common in RCCA) using PCR-direct sequencing (Moore et al.,
2012; Kuo et al., 2009). We identiﬁed a point mutation in PIK3CA
at exon 20 (M1004I); no mutations were found in VHL (Fig. 2B).
The key ﬁndings of this case of non-DES exposed PVCCA are (i) favor-
able prognosis with CCRT, (ii) extensive chromosomal instability with
CNA at loci of well-known cancer-related genes, and (iii) presence of
a PIK3CA mutation. Vaginal cancer patients are generally treated with
radiation (Creasman et al., 1998). Chemotherapy is infrequently used
in treatment because of the poor associated outcome (Creasman et al.,
1998; Renaud et al., 2009). However, the 5-year survival rate amongpatients with stage Ι PVCCA is only 56%, which is signiﬁcantly worse
than that for vaginal squamous cell carcinoma (Hanselaar et al., 1997).
Thus, an alternative therapeutic strategy is warranted. Recently, Ghia
et al. compared the prognoses associatedwith CCRT and radiotherapy be-
tween vaginal and cervical cancers, and suggested that the improvement
in prognosis was lower for vaginal cancer than for cervical cancer (Ghia
et al., 2011). However, multivariate analysis by histology suggested that
the increase in the progression-free interval associated with CCRT was
signiﬁcantly higher for adenocarcinoma (hazard ratio [HR], 0.05; 95%
conﬁdence interval [CI]: 0.004–0.56; P = 0.02) than for squamous cell
carcinoma (HR, 0.14, 95% CI: 0.02–1.20; P = 0.07). Thus, CCRT may be
a suitable option for PVCCA.
We analyzed the tumor for chromosomal CNA and genetic alter-
ations. Since non-DES-exposed PVCCA often coexists with congenital
genital tract anomalies, such as an ectopic ureteral oriﬁce to the vagina
(Uehara et al., 2010; Tanaka et al., 1994), we hypothesized that PVCCA
may possess genetic characteristics similar to urogenital CCA, such as
RCCA and OCCA. In this patient, we observed extensive chromosomal
imbalances, with a chromosomal gain at 20q and loss of heterozygosity
at 9p, both of which are common to OCCA. However, neither 3p loss nor
5q gainwas observed. These results suggest a similarity of chromosomal
imbalances between PVCCA and OCCA. To assess speciﬁc genetic alter-
ations common to RCCA and OCCA, we analyzed mutations in VHL
and PIK3CA and found that this PVCCA had a PIK3CAmutation (but not
a VHL mutation), further supporting the hypothesis that PVCCA and
OCCA are genetically similar.
Our study has several limitations. Since our ﬁndings are based on a
single case, given the rarity of PVCCA, the efﬁcacy of CCRT in PVCCA
Fig. 2.Genetic characteristics of the tumor. (A) The single nucleotidepolymorphism array revealed extensive chromosomal copynumber alterations. DNA from the lymphocyte pellet from
blood was used as a control. Alterations included chromosomal gain at 20q and loss of heterozygosity at 9p. (B) Left, polymerase chain reaction-direct sequencing of PIK3CA (exon 20)
showed a G to C substitution corresponding to a missense mutation (methionine changed to isoleucine at codon 1004 [M1004I]). Right, control sequencing data.
51Y. Ikeda et al. / Gynecologic Oncology Reports 10 (2014) 49–52should be further clariﬁed in larger prospective studies. Further, it is still
not clear whether non-DES-exposed PVCCA and DES-exposed PVCCA
have common genomic proﬁles. Additional analysis of a larger cohort
is warranted to elucidate the molecular characteristics of PVCCA.Conclusions
We report a favorable outcome in a case of non-DES-exposed PVCCA
treatedwith CCRT. The PVCCA described herein exhibited chromosomal
and genetic characteristics common to OCCA.Table 1
Loci of chromosomal copy number alternations.
Loci Cancer-related gene
Gain 10q22.1
11p13
20q11.21
20q13.13–20q13.33 ZNF217
LOH 1q32.1–1q41
8p22–8p11.22
9p22.1–9p21.3 CDKN2A/2B
9p24.3
11q13.5–11q23.3
12p13.33
19p13.3–19p13.12
Homozygous deletions 11q14.1
Copy number neutral LOH 1q41
9p24.3–9p22.1
12p13.33–12p13.31
16q12.1–16q24.2
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